June 2024

Zanidatamab demonstrated a median overall survival (OS) of 15.5 months in patients with centrally confirmed immunohistochemistry (IHC) 2+ or 3+ and a median OS of 18.1 months in patients with IHC 3+ tumors With approximately two years of median follow-up, as of July 28, 2023, median duration of res

Separate & Distinct from HARMONi-2 Announcement, HARMONi-A Showed Clinically Meaningful and Statistically Significant Benefit: PFS Hazard Ratio of 0.46  For Subset of Patients Previously Receiving 3rd Generation EGFR-TKI: PFS Hazard Ratio of 0.48 5.6% Treatment Discontinuation of Ivonescimab du

BEIJING, June 1, 2024 /PRNewswire/ — A news report from China Daily:  Had one never met “A Fu” in person but only heard his standard, fluent Beijing dialect as well as his knowledge of the capital, it would be hard to imagine that he is actually a UK citizen whose real name is Fra

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: